Results 11 to 20 of about 13,611 (195)

In vivo Molecular Imaging of Glutamate Carboxypeptidase II Expression in Re-endothelialisation after Percutaneous Balloon Denudation in a Rat Model [PDF]

Scientific Reports, 2018
The short- and long-term success of intravascular stents depends on a proper re-endothelialisation after the intervention-induced endothelial denudation.
Heike Endepols, Felix M. Mottaghy, Sakine Simsekyilmaz, Jan Bucerius, Felix Vogt, Oliver Winz, Raphael Richarz, Philipp Krapf, Bernd Neumaier, Boris D. Zlatopolskiy, Agnieszka Morgenroth   +10 more
doaj   +2 more sources

Dysregulation of glutamate carboxypeptidase II in psychiatric disease. [PDF]

Schizophr Res, 2008
Experimental evidence is beginning to converge on an important role for dysregulation of glutamate carboxypeptidase II (GCPII) in schizophrenia. The goal of this study was to determine GCPII levels in postmortem brain specimens of patients with schizophrenia, bipolar disorder or unipolar depression and age-matched control subjects. We used N-[N-(S)-1,3-
Guilarte TR, Hammoud DA, McGlothan JL, Caffo BS, Foss CA, Kozikowski AP, Pomper MG.   +6 more
europepmc   +4 more sources

Promoter analysis of human glutamate carboxypeptidase II. [PDF]

Brain Res, 2007
The expression of glutamate carboxypeptidase II (GCP II) is reduced in selective brain regions in schizophrenic patients. To investigate transcriptional mechanisms regulating the human GCP II gene, a 3460 bp DNA fragment comprised of the proximal 3228 bp of 5' untranscribed sequence and first 232 bp of 5' UTR portion of this gene was cloned into the ...
Han L, Wong DL, Tsai G, Jiang Z, Coyle JT.   +4 more
europepmc   +4 more sources

Inhibition of brain glutamate carboxypeptidase II (GCPII) to enhance cognitive function. [PDF]

Adv Pharmacol
Cognitive deficits are a class of symptoms present in a broad range of disorders that go largely unaddressed by current medications. Disruptions in executive function and memory can be detrimental to patient quality of life, so there is a large unmet medical need for novel therapies to improve cognitive performance.
Wiseman R, Bigos KL, Arnsten AFT, Slusher BS.   +3 more
europepmc   +3 more sources

Structural characterization of P1'-diversified urea-based inhibitors of glutamate carboxypeptidase II. [PDF]

Bioorg Med Chem Lett, 2014
Urea-based inhibitors of human glutamate carboxypeptidase II (GCPII) have advanced into clinical trials for imaging metastatic prostate cancer. In parallel efforts, agents with increased lipophilicity have been designed and evaluated for targeting GCPII residing within the neuraxis.
Pavlicek J, Ptacek J, Cerny J, Byun Y, Skultetyova L, Pomper MG, Lubkowski J, Barinka C.   +7 more
europepmc   +5 more sources

Glutamate carboxypeptidase II is not an amyloid peptide-degrading enzyme.

FASEB J, 2013
Glutamate carboxypeptidase II (GCPII) is an exopeptidase that catalyzes the hydrolysis of N ‐acetylated aspartate‐glutamate (NAAG) to N ‐acetyl aspartate (NAA) and glutamate.
Alt J, Stathis M, Rojas C, Slusher B.
europepmc   +4 more sources

N-substituted glutamyl sulfonamides as inhibitors of glutamate carboxypeptidase II (GCP2). [PDF]

Chem Biol Drug Des, 2011
Glutamate carboxypeptidase II (GCP2) is a membrane‐bound cell‐surface peptidase which is implicated in several neurological disorders and is also over‐expressed in prostate tumor cells. There is a significant interest in the inhibition of GCP2 as a means of neuroprotection, while GCP2 inhibition as a method to treat prostate cancer remains a topic of ...
Blank BR, Alayoglu P, Engen W, Choi JK, Berkman CE, Anderson MO.   +5 more
europepmc   +5 more sources

Targeting NAAG metabolism restores cognition and synaptic integrity in EcoHIV-infected mice [PDF]

Neurotherapeutics
Despite effective antiretroviral therapy, many people living with HIV (PLH) experience cognitive impairments, particularly in executive function and working memory.
Yuxin Zheng, Meixiang Huang, R Michael Maragakis, Peter Pietri, Yu Su, Jesse Alt, Ying Wu, Colin Finney, Diane E. Peters, Xiaolei Zhu, Rana Rais, Barbara S. Slusher   +11 more
doaj   +2 more sources

Inflammatory mechanisms underlying early Alzheimer’s disease pathology: evidence from the aging rhesus macaque brain [PDF]

Frontiers in Cellular Neuroscience
Inflammation plays a large role in the etiology of the late onset, sporadic form of Alzheimer’s disease (AD), yet these critical factors are not adequately modeled in mice where inflammatory mechanisms often differ widely from primates.
Dibyadeep Datta, Dibyadeep Datta, Min Wang, Amy F. T. Arnsten   +3 more
doaj   +2 more sources

Novel substrate-based inhibitors of human glutamate carboxypeptidase II with enhanced lipophilicity. [PDF]

J Med Chem, 2011
Virtually all low molecular weight inhibitors of human glutamate carboxypeptidase II (GCPII) are highly polar compounds that have limited use in settings where more lipophilic molecules are desired. Here we report the identification and characterization of GCPII inhibitors with enhanced liphophilicity that are derived from a series of newly identified ...
Plechanovová A, Byun Y, Alquicer G, Skultétyová L, Mlčochová P, Němcová A, Kim HJ, Navrátil M, Mease R, Lubkowski J, Pomper M, Konvalinka J, Rulíšek L, Bařinka C.   +13 more
europepmc   +5 more sources